Vaccine Manufacture and Supply – News and Features

Company accelerates the development and manufacturing of cell-based VLP-type vaccines using the MaxCyte Flow Electroporation Technology Platform.

Researchers have developed a menu of 61 new strains of genetically engineered bacteria that may improve the efficacy of vaccines for diseases such as flu, pertussis, cholera and HPV.

Companies to commercialize plant-based technologies for biopharmaceutical and vaccine manufacture.

UMN Pharma will produce a number of biosimilars using Catalent’s GPEx cell lines.

New and increasingly sophisticated vaccines are taking aim at a broad range of disease-causing pathogens, targeting them with greater effectiveness at lower cost and with improved measures to ensure safety.

Through establishing greater cooperation throughout the developing world on vaccine research and development.

Contract is to supply pre-pandemic and pandemic vaccine antigens and related services to the U.S. national stockpile.

Federal judge moves forward with meningococcal vaccine antitrust suit against Sanofi.

Alnylam Pharmaceutical received milestone payment from GSK as part of their ongoing collaboration to utilize Alnylam’s RNA interference (RNAi) technology to develop GSK’s cell-culture based influenza vaccine.

Innovation could allow quicker vaccine development to combat pandemics.